SCHEMBL1417464

SCHEMBL1417464

CC(C)(C)[Si](C)(C)Oc1cc(Br)cc(CO)c1

nearest known ligand 0.35

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.35
CA1 P00915 4/20 0.35
CA9 Q16790 4/20 0.35
PREP P48147 3/20 0.33
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6155473 0.90 CA12 (0.38) CA12CA1CA9PREPCYP4F2
SCHEMBL5921536 0.90 CA12 (0.38) CA12CA1CA9PREPCYP4F2
SCHEMBL17974012 0.85 CA12 (0.36) CA12CA1CA9PREPIDO1
SCHEMBL4404635 0.85 CA12 (0.36) CA12CA1CA9PREPIDO1
SCHEMBL23723314 0.82 CA12 (0.42) CA12CA1CA9PREP
SCHEMBL1416957 0.82 CA12 (0.42) CA12CA1CA9PREPIDO1
SCHEMBL4694107 0.79 IDO1 (0.38) IDO1
SCHEMBL5855438 0.78 PTGS2 (0.44) CA1CA9
SCHEMBL29851528 0.77 KDR (0.41) CA12CA1CA9IDO1
SCHEMBL559965 0.77 KDR (0.41) CA12CA1CA9IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 WO disclosed
US-8426473-B2 Phenoxy acetic acids as PPAR delta activators High Point Pharnaceuticals, LLC (US) 2013-04-23 US disclosed
US-8426473-B2 Phenoxy acetic acids as PPAR delta activators High Point Pharnaceuticals, LLC (US) 2013-04-23 US disclosed
US-8426473-B2 Phenoxy acetic acids as PPAR delta activators High Point Pharnaceuticals, LLC (US) 2013-04-23 US disclosed
US-20120232080-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
US-20120232080-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
US-8217086-B2 Phenoxy acetic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2012-07-10 US disclosed
US-8217086-B2 Phenoxy acetic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2012-07-10 US disclosed
EP-1899302-B1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS LLC (US) 2011-10-19 EP disclosed
US-20110183982-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2011-07-28 US disclosed
US-20110183982-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2011-07-28 US disclosed
US-7943669-B2 Phenoxy acetic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2011-05-17 US disclosed
US-7943669-B2 Phenoxy acetic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2011-05-17 US disclosed
EP-2298742-A1 Phenoxy acetic acids as PPAR delta activators High Point Pharmaceuticals, LLC (US) 2011-03-23 EP disclosed
US-20090192162-A1 Phenoxy Acetic Acids as PPAR Delta Activators TRANSTECH PHARMA, INC. (NC) 2009-07-30 US disclosed
US-20090192162-A1 Phenoxy Acetic Acids as PPAR Delta Activators TRANSTECH PHARMA, INC. (NC) 2009-07-30 US disclosed
EP-1899302-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS Novo Nordisk A/S (DK) 2008-03-19 EP disclosed
WO-2007003581-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192162-A1 Phenoxy Acetic Acids as PPAR Delta Activators PPARA, PPARG, PPARD CA12 4294/4885CA1 3566/4885CA9 2721/4885
US-20120232080-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS PPARA, PPARG, PPARD CA12 4294/4885CA1 3566/4885CA9 2721/4885
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CA12 4564/4885CA1 4815/4885CA9 2940/4885
US-20110183982-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS PPARA, PPARG, PPARD CA12 4294/4885CA1 3566/4885CA9 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.